News

Black and white photo of a bearded man in very 70s apparel standing in front of a banner with "David Baltimore" and the mirror image text'

Remembering David Baltimore

MIT Koch Institute

With sadness, the Koch Institute marks the passing of Professor David Baltimore. A founding faculty member and formative influence behind the MIT Center for Cancer Research, he was not only a ground-breaking researcher but also a compelling and thoughtful voice for science. 

His discovery of reverse transcriptase changed the prevailing scientific dogma, earned him a 1975 Nobel Prize, and directly enables work in life sciences and biomedical laboratories everywhere. His decades-long advocacy work impacted national policy debates on topics such as recombinant DNA research, the AIDS epidemic, and genome editing.

Filter by

Filter by Title/Description

Filter by Topic

Filter by Year

A Better, Faster, Cheaper CAR

MIT News

The Chen Lab is developing CAR NK-cells, a cancer immunotherapy approach already in clinical trials that offers notable benefits over approved CAR T-cell treatments. Their newly published study, which appears in Nature Communications, identifies genetic modifications that can make CAR NK-cells more effective, less prone to rejection or side effects, and simpler to produce.  The streamlined, one-step engineering innovation could enable development of off-the-shelf therapies that can be given to patients at diagnosis, several weeks sooner than traditionally engineered CAR NK- or CAR T-cells. The Chen lab and their clinical collaborators hope to run a patient trial of this new approach.

This research was funded in part by the Koch Institute Frontier Research Program through the Kathy and Curt Marble Cancer Research Fund and the Elisa Rah (2004, 2006) Memorial Fund

Out of This World: Breast Cancer Detection Goes to Space 

Good Good Good News

Cima Lab alum Canan Dagdeviren launched a breast-cancer–detecting bra into space aboard Blue Origin's all-female crew in April 2025. This wearable ultrasound patch enables early detection of breast cancer. In microgravity, “10 years of tumor growth can occur in 10 days,” allowing scientists to fast-track breakthroughs in early detection back on Earth.  

Biogen Expansion Signals Optimism for Kendall Square

MIT News

Biogen, co-founded in 1978 by the Koch Institute's Phillip Sharp and Harvard's Wally Gilbert, broke ground on its new Kendall Square headquarters in September. The 580,000-square-foot complex, expected to open in 2028, reflects optimism for Cambridge’s future as a global biotech hub and a continued engine for innovation.

Precision gene editing

MIT News

Robert Langer, Phillip Sharp, and research scientist Vikash Chauhan developed an engineered prime editing system, reported in Nature, that reduces unintended DNA changes by up to 60-fold. The new gene editor could make it easier to explore cell biology questions, such as how populations of cancer cells evolve, as well as develop gene therapy treatments for cancer and other diseases.

FDA approves bladder cancer drug delivery device

MIT News

The FDA approved Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system), a bladder cancer treatment system that originated in the lab of Michael Cima. Developed in the thesis work of KI alum Heejin Lee as well as at KI spinout TARIS Biomedical, the pretzel-shaped device is made of a special alloy with "shape memory," which folds in the bladder after insertion, delivering drugs over slowly over three weeks, to be repeated at the physician's discretion.  This approach offers safer and more effective treatment for one of the most expensive cancers, marked by high recurrence rates. In one study, 82% of patients treated with the system showed no evidence of cancer, with more than half remaining cancer-free nine months later. 

Therapeutic vaccine elicits strong response

NBC Nightly News

NBC Nightly News covers robust early results from Elicio's clinical trials of its vaccine for treating pancreatic and colorectal cancer. In the Phase I trial, the vaccine generated strong anti-cancer T-cell responses in nearly 85% of patients, extending both recurrence-free and overall survival time. The vaccine builds on research carried out at the Koch Institute and funded in part by the Bridge Project.

Antibodies make better bottlebrushes

MIT News

Adapting his bottlebrush polymer drug delivery platform, Jeremiah Johnson has engineered new antibody-targeted particles that outperform existing antibody drug conjugates to deliver concentrated chemotherapy directly to cancer cells. The study, which appears in Nature Biotechnology, shows that each antibody-guided particle can carry dozens or hundreds of drug molecules tethered to polymer chains, eradicating most tumors in mouse models. This work was supported in part by the Koch Institute Frontier Research Program.

PanTher launches Phase 1b trial

BioSpace

PanTher Therapeutics, a spinout from the Edelman and Langer Labs, has initiated a Phase 1b trial of its absorbable, high-dose chemotherapy patch for pancreatic cancer. The thin-film formulation is designed to target tumors locally while limiting systemic side effects. Early work on the film was supported by the Bridge Project.

Get a grip

MIT News

Attaching to bendable, bumpy, uneven, or otherwise complex surfaces can be a critical challenge for drug delivery, medical implants, and other fields. Drawing KI Image Awards-winning inspiration from fishes including remora and gourami, Traverso lab members Troy Ziliang Kang, Ben Muller, and colleagues have developed a mechanical adhesive system that could be used for delivering medicines in the gastrointestinal tract or aquatic monitoring.

Putting liver cells on the clock

MIT News

The Bhatia Lab developed a platform where human-derived liver cells mimic in vitro the daily, cyclical variations seen in the body. The system, described in Science Advances, can be used to study the effects of circadian rhythms on drug metabolism, as well as the timing and size of immune responses to liver infections.